New Blood Test Achieves 90% Accuracy in Diagnosing Alzheimer’s Disease, Outperforming Standard Methods

The landscape of Alzheimer’s disease care has long been bottlenecked by a fundamental challenge: accurately diagnosing the condition before it causes irreversible cognitive decline. Historically, confirming the presence of Alzheimer's pathology required either an expensive amyloid PET scan or an invasive lumbar puncture to extract cerebrospinal fluid. Because these tools are costly and difficult to access, most patients rely on standard clinical evaluations, which often lead to misdiagnosis or delayed treatment.[1][6]

A landmark study published in JAMA Neurology and presented at the Alzheimer’s Association International Conference has validated a transformative alternative. A commercially available blood test, known as PrecivityAD2, has demonstrated approximately 90% accuracy in identifying Alzheimer’s disease in patients experiencing cognitive symptoms.[2][3]

The prospective study, led by researchers at Lund University in Sweden, evaluated 1,213 patients who were seeking care for mild memory symptoms. The cohort was split between primary care clinics and specialist memory care centers, providing a real-world stress test for the diagnostic tool.[2][4]

The results revealed a stark contrast between the blood test and the current standard of care. When primary care physicians relied on traditional methods—including clinical examinations, cognitive testing, and CT scans—they correctly identified Alzheimer’s disease only 61% of the time.[2][3]

Even dementia specialists, who possess extensive training in neurodegenerative diseases, achieved only a 73% accuracy rate using those same standard clinical tools without the aid of advanced biomarkers. In both settings, the blood test's 90% accuracy rate significantly outperformed human clinical judgment.[2][3]

The mechanism behind the PrecivityAD2 test relies on high-resolution mass spectrometry to detect microscopic proteins that spill from the brain into the bloodstream. Specifically, the test measures the ratio of two types of amyloid beta proteins (Aβ42 and Aβ40).[1][5]

In addition to amyloid, the test quantifies the proportion of a specific tau protein known as p-tau217 relative to non-phosphorylated tau. The abnormal buildup of amyloid plaques and tau tangles are the two defining pathological hallmarks of Alzheimer’s disease.[1][5]

These precise molecular measurements are fed into a proprietary algorithm to generate an Amyloid Probability Score 2 (APS2). This single binary score indicates the likelihood of amyloid plaques in the brain, matching the diagnostic reliability of a PET scan or spinal tap.[3][5]

The clinical implications of this accuracy are profound. In specialist clinics that lack easy access to PET scans or cerebrospinal fluid testing, the blood test can serve as a definitive diagnostic tool. In well-resourced clinics, it can largely replace those invasive and expensive procedures for the vast majority of patients.[3][6]

Crucially, the study found that the blood test performed equally well in primary care settings as it did in specialist clinics. It maintained its high accuracy regardless of the patients' underlying medical comorbidities, such as cardiovascular disease, diabetes, or chronic kidney disease.[2][5]

This shift toward primary care is vital because community clinics are where most individuals first seek help for memory loss. By equipping primary care doctors with a highly accurate diagnostic tool, the healthcare system can dramatically reduce the time it takes for a patient to receive a definitive answer.[1][2]

Speed and accuracy in diagnosis have never been more critical. The recent regulatory approval of disease-modifying immunotherapies, which can slow the progression of Alzheimer's, requires strict confirmation of amyloid pathology before treatment can begin. Without a confirmed biomarker diagnosis, patients are ineligible for these drugs.[2][6]

Despite the breakthrough, researchers emphasize transparent boundaries for the test's use. The blood test is currently validated only for individuals who are already exhibiting signs of mild cognitive impairment or dementia. It is not intended for asymptomatic individuals or the "worried well" seeking to predict their future risk of dementia.[3][6]

Commercially, the landscape is rapidly adapting to this new technology. The test is now available for prescription for patients aged 50 and older who are undergoing evaluation for cognitive decline. Major health insurers have also begun issuing medical policies to cover the test, recognizing its potential to streamline care and reduce overall diagnostic costs.[5][6]

As clinical guidelines evolve to incorporate blood biomarkers as a tier-one diagnostic standard, the era of relying solely on cognitive tests and subjective clinical judgment is ending. For millions of families facing the daunting prospect of memory loss, this blood test offers a faster, clearer, and far less daunting path to answers.[4][6]